Inhibition of HER2 may play a potential role in antiproliferation of tumor, and inhibition of EGFR and combination therapy with TKIs could be useful in EGFR- or HER2-overexpressing ESCC. Here, ERBB2 is linked to esophageal squamous cell carcinoma.